Penumbra Dirección

Dirección controles de criterios 4/4

El CEO de Penumbra's es Adam Elsesser , nombrado en Jun 2004, tiene una permanencia de 19.83 años. compensación anual total es $601.62K, compuesta por 99.7% salario y 0.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.49% de las acciones de la empresa, por valor de €183.19M. La antigüedad media del equipo directivo y de la junta directiva es de 3.9 años y 8.1 años, respectivamente.

Información clave

Adam Elsesser

Chief Executive Officer (CEO)

US$601.6k

Compensación total

Porcentaje del salario del CEO	99.7%
Permanencia del CEO	19.9yrs
Participación del CEO	2.5%
Permanencia media de la dirección	4yrs
Promedio de permanencia en la Junta Directiva	8.2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Adam Elsesser en comparación con los beneficios de Penumbra?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$93m
Dec 31 2023	US$602k	US$600k	US$91m
Sep 30 2023	n/a	n/a	US$41m
Jun 30 2023	n/a	n/a	US$29m
Mar 31 2023	n/a	n/a	US$6m
Dec 31 2022	US$602k	US$600k	-US$2m
Sep 30 2022	n/a	n/a	-US$31m
Jun 30 2022	n/a	n/a	-US$19m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$498k	US$496k	US$5m
Sep 30 2021	n/a	n/a	US$34m
Jun 30 2021	n/a	n/a	US$16m
Mar 31 2021	n/a	n/a	-US$5m
Dec 31 2020	US$219k	US$217k	-US$16m
Sep 30 2020	n/a	n/a	-US$10m
Jun 30 2020	n/a	n/a	US$11m
Mar 31 2020	n/a	n/a	US$39m
Dec 31 2019	US$727k	US$725k	US$48m
Sep 30 2019	n/a	n/a	US$45m
Jun 30 2019	n/a	n/a	US$15m
Mar 31 2019	n/a	n/a	US$12m
Dec 31 2018	US$727k	US$725k	US$7m
Sep 30 2018	n/a	n/a	US$9m
Jun 30 2018	n/a	n/a	US$28m
Mar 31 2018	n/a	n/a	US$13m
Dec 31 2017	US$727k	US$725k	US$5m

Compensación vs. Mercado: La compensación total de Adam($USD601.62K) está por debajo de la media de empresas de tamaño similar en el mercado German ($USD3.54M).

Compensación vs. Ingresos: La compensación de Adam ha sido consistente con los resultados de la empresa en el último año.

CEO

Adam Elsesser (61 yo)

19.9yrs

Permanencia

US$601,620

Compensación

Mr. Adam Elsesser serves as President at Penumbra, Inc. since May 2020. He Co-Founded Penumbra, Inc. in 2004 and has been its Chief Executive Officer and Director since June 2004. Mr. Elsesser has been the...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Adam Elsesser	Co-Founder	19.9yrs	US$601.62k	2.48% $ 188.0m
Arani Bose	Co-Founder & Director	19.9yrs	US$233.99k	1.05% $ 79.6m
Maggie Yuen	Chief Financial Officer	4.4yrs	US$666.04k	0.016% $ 1.2m
Lambert Shiu	Chief Accounting Officer	4.4yrs	US$539.94k	0.041% $ 3.1m
Johanna Roberts	Executive VP	5.7yrs	US$661.89k	0.14% $ 10.7m
Ben Sorci	Executive Vice President of Operations	3.3yrs	sin datos	sin datos
Pankaj Tiwari	Executive VP & Chief Information Officer	2.3yrs	sin datos	sin datos
Jee Hamlyn-Harris	Investor Relations Officer	no data	sin datos	sin datos
Ben Tompkins	Executive Vice President of Development	3.3yrs	sin datos	sin datos
Gita Barry	President of Immersive Healthcare	3.3yrs	sin datos	sin datos
Shruthi Narayan	Executive VP & GM of Interventional	1.3yrs	sin datos	sin datos
Jason Mills	Executive Vice President of Strategy	4yrs	sin datos	sin datos

4.0yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0P8 se considera experimentado (3.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Adam Elsesser	Co-Founder	19.9yrs	US$601.62k	2.48% $ 188.0m
Arani Bose	Co-Founder & Director	19.9yrs	US$233.99k	1.05% $ 79.6m
Harpreet Grewal	Independent Director	9.1yrs	US$241.49k	0.024% $ 1.8m
Thomas Wilder	Independent Director	7.3yrs	US$258.99k	0.012% $ 923.6k
Don Kassing	Presiding Independent Director	16.3yrs	US$246.49k	0.024% $ 1.8m
Surbhi Sarna	Independent Director	4.8yrs	US$248.99k	0.0063% $ 480.7k
Bridget O'Rourke	Independent Director	7.1yrs	US$263.99k	0.011% $ 855.4k
Janet Leeds	Independent Director	5.3yrs	US$251.49k	0.012% $ 938.7k

8.2yrs

Permanencia media

59.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 0P8 se considera experimentada (8.1 años de antigüedad promedio).

Penumbra Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Penumbra, Inc., Annual General Meeting, Jun 05, 2024

Insufficient new directors

Insufficient new directors

Penumbra, Inc., Annual General Meeting, Jun 01, 2022

Lynn Rothman, the Executive Vice President and Chief Business Officer of Penumbra, Inc., Notifies Her Departure

Insufficient new directors

Recent updates

First quarter 2024 earnings released: EPS: US$0.28 (vs US$0.22 in 1Q 2023)

Penumbra, Inc. Reiterates Earnings Guidance for the Year 2024

Penumbra, Inc., Annual General Meeting, Jun 05, 2024

Penumbra, Inc. Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots

Penumbra, Inc. to Report Q1, 2024 Results on May 07, 2024

Full year 2023 earnings released: EPS: US$2.37 (vs US$0.053 loss in FY 2022)

Penumbra, Inc. Provides Earnings Guidance for the Full Year 2024

Penumbra, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Penumbra, Inc. Announces First Patient in STORM-PE RCT Enrolled Evaluating Penumbra's Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash for Treatment of Acute Pulmonary Embolism

Penumbra, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.24 (vs US$0.06 loss in 3Q 2022)

Penumbra, Inc. Announces Latest STRIKE-PE Data Evaluating Penumbra's Indigo Aspiration System with Lightning

Now 27% undervalued after recent price drop

Penumbra, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: EPS: US$0.49 (vs US$0.098 loss in 2Q 2022)

Penumbra, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Penumbra Expands Computer-Aided Thrombectomy Offerings with Lightning Bolt 7 Technology Designed to Rapidly Remove Blood Clots with Modulated Aspiration

Penumbra, Inc. Updates Revenue Guidance for the Full Year 2023

First quarter 2023 earnings released: EPS: US$0.22 (vs US$0.002 in 1Q 2022)

Full year 2022 earnings released: US$0.053 loss per share (vs US$0.14 profit in FY 2021)

Penumbra, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Penumbra, Inc. Launches Latest Innovation in Mechanical Thrombectomy, Lightning Flash

Insufficient new directors

Penumbra, Inc. Launches First Hands-Free, Full Body Virtual Reality-Based Offering for Rehabilitation, Expanding Real System Platform

Third quarter 2022 earnings released: US$0.06 loss per share (vs US$0.24 profit in 3Q 2021)

Penumbra, Inc. Provides Revenue Guidance for the Year 2023

Penumbra, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Penumbra, Inc. Announces European Launch of Red Reperfusion Catheters for Stroke Care

Penumbra, Inc. Announces Latest Data Demonstrates Penumbra System and RED Reperfusion Catheters Effective for Broad Stroke Care

Second quarter 2022 earnings released: US$0.098 loss per share (vs US$0.25 profit in 2Q 2021)

Penumbra, Inc. Updates Earnings Guidance for the Full Year 2022

Penumbra, Inc. to Report Q2, 2022 Results on Aug 04, 2022

First quarter 2022 earnings released: EPS: US$0.002 (vs US$0.33 in 1Q 2021)

Insufficient new directors

Penumbra, Inc., Annual General Meeting, Jun 01, 2022

Lynn Rothman, the Executive Vice President and Chief Business Officer of Penumbra, Inc., Notifies Her Departure

Penumbra, Inc. to Report Q1, 2022 Results on May 03, 2022

Penumbra Introduces Next Generation REAL® y-Series™, Expanding Virtual Reality Healthcare Platform

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Penumbra, Inc. Provides Earnings Guidance for the Year 2022

Insufficient new directors

Penumbra, Inc. to Report Q4, 2021 Results on Feb 22, 2022

Third quarter 2021 earnings released: EPS US$0.24 (vs US$0.24 loss in 3Q 2020)

Penumbra, Inc. Introduces REAL® i-Series™, Expanding Real Immersive System to Support Broad Range of Care Providers and Mental Health Professionals

Second quarter 2021 earnings released: EPS US$0.25 (vs US$0.34 loss in 2Q 2020)

Penumbra Receives FDA Clearance for RED 62 Reperfusion Catheter, Enabling Physicians to Address Broad Range of Stroke Patients

First quarter 2021 earnings released: EPS US$0.33 (vs US$0.041 in 1Q 2020)

Penumbra, Inc. Raises Earnings Guidance for 2021

Penumbra, Inc. Announces U.S. Commercial Availability of INDIGO System Lightning 7

Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Penumbra, Inc

Full year 2020 earnings released: US$0.44 loss per share (vs US$1.39 profit in FY 2019)

Revenue beats expectations

Kessler Topaz Meltzer & Check, LLP Alerts Investors That Securities Fraud Class Action Lawsuit has Been Filed Against Penumbra, Inc

Block & Leviton LLP Announces Lawsuit for Violation of the Federal Securities Laws Has Been Filed Against Penumbra, Inc. and Certain of Its Executives

Penumbra, Inc. to Report Q4, 2020 Results on Feb 23, 2021

New 90-day high: €240

ClaimsFiler Reminds Penumbra, Inc. Investors Of Lead Plaintiff Deadline in Class Action Lawsuits

Genesis Medtech Collaborates with Penumbra to Expand Neurovascular Market in China

Saxena White P.A. Files Securities Fraud Class Action Against Penumbra, Inc

New 90-day low: €141

Penumbra, Inc. Announces Penumbra JET 7 Reperfusion Catheter with Xtra Flex Technology Voluntary Recall

New 90-day low: €155

Penumbra’S Newest Generation of Indigo Aspiration System Receives FDA Clearance for Pulmonary Embolism

New 90-day high: €226

Penumbra, Inc. Announces Partnership with RapidAI to Enable Faster Clinical Decision-Making for Pulmonary Embolism

Third quarter 2020 earnings released: US$0.24 loss per share

Revenue beats expectations

Penumbra, Inc. to Report Q3, 2020 Results on Oct 28, 2020